Spitzer G, Dunphy F R, Bowers C E, Adkins D R
Division of Bone Marrow Transplantation, St. Louis University School of Medicine, Missouri 63110-0250.
Med Oncol. 1994;11(2):53-62. doi: 10.1007/BF02988831.
We describe some issues of ongoing studies and results in metastatic and high-risk breast cancer. Caution should be used to not over interpret the outcomes of these data given the patient selection. In other tumors with lesser developed studies, such as with ovarian cancer, non seminomatous germ cell tumors (NSGC), childhood sarcoma, melanoma and limited small cell carcinoma, promising outcomes in small phase II studies are identified and proposed or potential studies comparing high-dose therapy to conventional are outlined. High-dose therapy with either peripheral blood stem cell support (PBSC) or autologous bone marrow transplantation (ABMT) in Phase II studies on a diverse array of solid tumors shows exciting promise of long-term, disease-free survival. Comparative studies in early-stage patients are urgently needed to confirm these outcomes.
我们描述了转移性和高危乳腺癌正在进行的研究中的一些问题及结果。鉴于患者选择情况，应谨慎对待这些数据结果，避免过度解读。在其他研究开展较少的肿瘤中，如卵巢癌、非精原性生殖细胞肿瘤（NSGC）、儿童肉瘤、黑色素瘤和局限性小细胞癌，已在小型II期研究中发现了有前景的结果并提出建议，或概述了比较高剂量疗法与传统疗法的潜在研究。在针对多种实体瘤的II期研究中，采用外周血干细胞支持（PBSC）或自体骨髓移植（ABMT）的高剂量疗法显示出长期无病生存的令人兴奋的前景。迫切需要在早期患者中开展比较研究以证实这些结果。
